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Abstract: Deep brain stimulation (DBS) has proved useful for several movement disorders
(Parkinson’s disease, essential tremor, dystonia), in which first and/or second line pharmacological
treatments were inefficacious. Initial evidence of DBS efficacy exists for refractory obsessive-
compulsive disorder, treatment-resistant major depressive disorder, and impulse control disorders.
Ethical concerns have been raised about the use of an invasive surgical approach involving the central
nervous system in patients with possible impairment in cognitive functioning and decision-making
capacity. Most of the disorders in which DBS has been used might present with alterations in memory,
attention, and executive functioning, which may have an impact on the mental capacity to give
informed consent to neurosurgery. Depression, anxiety, and compulsivity are also common in DBS
candidate disorders, and could also be associated with an impaired capacity to consent to treatment
or clinical research. Despite these issues, there is limited empirical knowledge on the decision-making
levels of these patients. The possible informed consent issues of DBS will be discussed by focusing
on the specific treatable diseases.
Keywords: informed consent; decision-making capacity; deep brain stimulation
1. Introduction
In the last two decades, a growing interest emerged for deep brain stimulation (DBS) in the
treatment of movement and psychiatric disorders [1–3]. Despite significant advances in DBS use,
surgical procedures, and outcomes, there is a substantial lack of data concerning the decision-making
ability of patients undergoing DBS [4].
Different levels of evidence have highlighted the possible benefits of DBS in patients with
Parkinson’s disease (PD) [5,6], essential tremor (ET) [7,8], and dystonia [9–12] who experience serious
complications, or when standard pharmacological treatments were inefficacious. DBS is an accepted
treatment for refractory obsessive-compulsive disorder (OCD) [13], while still limited data from
research trials or case reports showed possible efficacy for treatment-resistant major depressive disorder
(MDD), Tourette syndrome (TS), and impulse control disorders such as addiction, anorexia nervosa,
schizophrenia, and anxiety disorders [3].
DBS received the U.S. Food and Drug Administration (FDA) approval for the treatment of
patients with PD (2002) and ET (1997), as well as humanitarian device exemption for dystonia (2003)
and treatment-resistant OCD (2009) [14]. The specific risk and benefit profile of DBS for each disease in
which it has been used is currently studied and debated. It must be underlined that DBS for movement
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disorders has involved significantly more patients than psychiatric disorders, with a rate of accrual of
more than 10,000 per year [1].
Both improvement and worsening of cognitive and affective symptoms, as well as impulse control
disorders have been reported post-DBS [1]; however, most of the evidence indicates that DBS is
beneficial particularly in movement disorders, with a minority of reports indicating the worsening of
symptoms. Issues in postoperative management and rehabilitation programs also exist, and should
be appropriately evaluated in the acquisition of consent to the intervention [15,16]. Postoperative
management problems might also present in successfully treated patients, including those presenting
a “burden of normality” syndrome, a term that refers to the possible patients’ difficulty to adapt from
being chronically ill to a symptoms-free status [17]. Adaptive DBS has been recently proposed to widen
the DBS therapeutic window and limit side effects; nonetheless, there is scarce evidence concerning its
long-term efficacy and safety profile [18].
Candidate patients might present difficulty in properly understanding and evaluating information
pertaining to the surgical procedure, including possible short and long-term consequences, as well as
the experimental nature of the research in those disorders in which DBS has not yet been approved [19].
The tendency to overlook the distinction between research and ordinary treatment, a process defined
as therapeutic misconception [20], is of particular importance for DBS in psychiatric disorders in view
of the experimental nature of DBS in such diseases. Therapeutic misconception has been reported in
patients with mood disorders undergoing DBS [21], but it has not been evaluated in other disorders,
although depressive symptoms are frequently reported.
Patients with a long history of illness and characterized by poor response to previous treatments,
may present frustration, alteration, of expectation in an optimistic or negative way, which may
contribute in altering their mental capacity to adequately consent to treatment or clinical research [22].
Affective symptoms associated with the underlying pathology such as anxiety and mood alterations
could also compromise patients’ treatment decision-making capacity [23].
In the present work, we will first synthetically discuss the informed consent doctrine with a
specific focus on patients’ decision-making capacity. In the second section, we will focus on the
principal disorders in which DBS has been used by synthetically reviewing existing data focusing on
indications—possibly associated cognitive and affective disorders—which might impact in patients’
decision-making capacity. We will also underline the possible benefits and risks of such information
being a prerequisite for the acquisition of a valid informed consent.
2. Informed Consent and Decision-Making Capacity
Informed consent is a prerequisite to any diagnostic, therapeutic, and clinical research procedure.
To provide valid informed consent, several components are required, including: voluntariness of
decision-making process, accurate and complete information disclosure, and the patient’s mental
capacity to consent [24]. The capacity to give informed consent has been defined as a multidimensional
construct encompassing several abilities [23].
The first of these abilities includes the patient (A) understanding the main characteristics of the
disorder (diagnosis) and treatment; in the case of clinical research, this includes the nature of the
project, the effects on individualized care, and the ability to withdraw. Information disclosure, in the
case of DBS must include the characteristics of the surgical procedure and anaesthesia, possible risks
and benefits, treatment alternatives, and predictable outcomes. A capable patient must prove able to
understand and retain such information. Second, the patient must (B) appreciate the relevance and
actual applicability of the previously disclosed information for the specific patient’s clinical condition.
The patient must prove able to evaluate the actual presence of the disease that has been diagnosed,
as well as the usefulness of the proposed treatment with associated benefits and risks. In the case of
clinical research, the patient must evaluate that the objective might not result in personal benefit or
even cause the possibility of reduced benefit, and that withdrawal is possible. Third, (C) a rational,
logical reasoning process pertaining to the choices must be provided by the patient, including the
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ability to make assumptions on the possible everyday effect of treatments (or no treatment), and
compare different treatment alternatives and possible outcomes. (D) Finally, a valid informed consent
requires the ability to express a choice in a personal, undeleted, unambivalent way.
Several tools exist to measure patients’ decision-making capacity for treatment or clinical
research [25]; the MacArthur Competence Assessment Tool for Clinical Research (MacCAT-CR) [26]
and for treatment (MacCAT-T) [27] have the greatest empirical support.
Among the possible characteristics associated with the mental incapacity to consent, cognitive
dysfunction has been widely acknowledged as a factor of primary importance in psychiatric and
non-psychiatric samples [28–32]. Decisional capacity requires the intervention of multiple domains of
mental functioning, such as will, inhibition, abstract reasoning, concept formation, prediction, and
planning, which are strictly linked to an individual’s executive functions. Executive dysfunction has
been linked to reduced or impaired treatment decision-making in psychiatric patients [31], as well as
in possible DBS candidate patients [33]. Specific symptoms, such as mania and psychosis, rather than
specific diagnoses, have been associated with the incapacity to give valid informed consent [34,35].
In addition to individual features, environmental factors could play a role in determining the
variability of patients’ capacity to consent to treatment or clinical research, including the complexity
of disclosed information, type of clinical setting, and quality of consent forms and disclosing
procedures [36,37].
There is evidence supporting the frequent occurrence of cognitive impairment and psychiatric
symptoms in several DBS candidate diseases such as PD [1,38–40], dystonia [41–46], and
ET [47–50]. Thus, the risk for mental incapacity to consent should be carefully evaluated in such
clinical populations undergoing DBS. The complexity of information pertaining to the DBS procedure
and possible outcomes, including a margin of uncertainty concerning DBS targeting and stimulation
designs, might require a significant cognitive and affective effort to be adequately appreciated and
rationally manipulated.
3. Informed Consent Issues in DBS Candidate Diseases
3.1. Parkinson’s Disease
Parkinson’s disease is a chronic neurodegenerative disease, with 1% prevalence in people over
60 years [51]. There is general agreement in considering PD not just a movement disorder, but also
a systemic disease characterized by numerous non-motor symptoms, such us anxiety, depression,
apathy, sleep disturbances, autonomic dysfunction, and cognitive impairment (executive dysfunction,
memory impairment, visuospatial dysfunction) [1]. The limits of pharmacotherapies, including the
progressive loss of efficacy, dyskinesia, drug-induced psychosis, and compulsive behaviors have led
an increasing use of DBS in PD. PD is also the pathology in which DBS has been most used. DBS in PD
is supported by evidence from controlled trials [52]. The main targets for DBS in Parkinson’s disease
are the globus pallidus pars interna (GPi) and the subthalamic nucleus [1]. Different targets present
different risks and benefits profiles that should be acknowledged in informed consent acquisition
procedures [53].
The capacity to provide valid consent to treatment in patients with PD may be altered by some
frequent clinical features associated with the disease, such as cognitive impairment, mood alterations,
anxiety, psychotic symptoms, and behavioral alterations (Table 1). Almost one-fourth of the patients
with PD have a mild cognitive impairment at the time of diagnosis, and about 90% of patients with
end-stage PD suffer from major neurocognitive disorder [38].
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Table 1. Cognitive and neuropsychiatric symptoms of deep brain stimulation (DBS) candidate diseases
and their possible impact on neurosurgical treatment and research decision-making capacity.
Cognitive and
Neuropsychiatric Symptoms
Evidence for DBS
Candidate Disease
Possible Impact on Informed Consent
Decision-Making
Cognitive
alterations/cognitive
impairment (attention,
memory, executive functions,
visuospatial abilities, etc.)
Parkinson’s disease; essential
tremor; dystonia; major
depressive disorder
Altered understanding/retaining of
treatment-related information; altered
evaluation of possible risks and benefits;
altered reasoning; altered ability to express a
choice; therapeutic misconception. Major
neurocognitive disorder/dementia might
imply full incapacity
Mood alterations
Parkinson’s disease; essential
tremor; dystonia;
obsessive-compulsive disorder;
major depressive disorder
Optimistic bias (excitement); pessimistic bias
(depression); altered evaluation of his/her
condition and likely consequences of the
intervention; impaired reasoning; impaired
expressing a choice; therapeutic
misconception
Anxiety
Parkinson’s disease; essential
tremor; dystonia;
obsessive-compulsive disorder;
Tourette syndrome; major
depressive disorder
Altered evaluation of patients’ condition and
likely consequences of the intervention;
impaired expression of a choice; therapeutic
misconception
Psychotic symptoms Parkinson’s disease; majordepressive disorder
Impaired evaluating, reasoning, expressing a
choice (might include also impaired
understanding in case of distracting
hallucinations or pervasive delusions);
therapeutic misconception
Behavioral alterations
Parkinson’s disease; dystonia,
obsessive-compulsive disorder;
major depressive disorder
Impaired understanding, evaluation,
reasoning, expressing a choice
Note: Since DBS candidate diseases might coexist with other neuropsychiatric disorders e.g., essential tremor and
mild cognitive impairment or dementia, the comorbid disease might affect the informed consent decisional capacity.
Alterations in executive functioning, including set shifting, planning, inhibition, and conflict
resolution have been reported in patients with PD, as well as impairment in working memory,
visuospatial abilities, and alterations in language [39]. The presence of specific alterations in these
domains should be carefully evaluated, since it could determine an impairment of understanding
and retaining of treatment-related information, evaluating possible risks and benefits, as well as of
reasoning and the ability to express a choice.
DBS of the subthalamic nucleus in patients with PD is moreover associated with a progressive
decrease in verbal fluency, executive functions, and working memory [54,55], implying the need for an
appropriate assessment in patients who already have alterations in these domains. The presence of
a major neurocognitive disorder could imply incapacity, and the consequent necessity of supported
decision-making. Nonetheless, a recent pilot trial of the nucleus basalis of Meynert DBS in patients
with Parkinson disease dementia enrolled six patients who have been considered capable of giving
informed consent to the randomized clinical trial [56]. We believe that the level of decision-making
capacity in patients with PD and major neurocognitive disorder should be carefully considered in
studies on larger samples that include a specific assessment of their capacity to consent.
Depressive symptoms are one of the most frequent non-motor manifestations of PD, with 20%
of cases suffering from MDD [40]; it could also alter treatment decision-making process and should
be carefully evaluated. Depressive symptoms can lead to a pessimistic bias (i.e., excessive negative
expectations), to an altered evaluation of subjective clinical condition and prognosis, as well as the
likely consequences of the intervention, or to an alteration in reasoning and the ability to express a
choice (Table 1). The prevalence of anxiety disorders in patients with PD is about 30%, and among
these, the most represented disorders are generalized anxiety disorder and social phobia [57]. Anxiety
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symptoms can also have a negative impact on the ability to consent to treatment by interfering with
understanding, appreciating, reasoning, and expressing choice abilities.
Psychotic symptoms are also frequent in patients with PD; among these, visual hallucinations
and delusions are predominant, while auditory hallucinations are less frequent. Since there is much
evidence linking the presence of psychotic symptoms to changes in treatment decision-making capacity
in psychiatric disorders [35], the presence of psychotic symptoms in PD could be associated with
potential alterations in informed consent decision-making, given their acknowledged effect in consent
decision-making in psychiatric disorders.
A recent study on patients’ preferences comparing hypothetical treatment with DBS, medicine
pump, or oral therapy showed that the decisions were associated with specific potential adverse
effects [58]. This result is deserving of further attention, since it has possible implications also in
patients’ capacity to consent/dissent to treatment.
3.2. Dystonia
Dystonia is a movement disorder that is characterized by sustained or intermittent muscle
contractions causing abnormal, often repetitive, movements, postures, or both [59]. Patients are
classified according to the clinical characteristics (age at onset, body distribution, temporal pattern,
associated features) and etiology (nervous system pathology, inherited or acquired) [60]. In addition to
motor symptoms, patients with idiopathic dystonia often present non-motor symptoms, including
neuropsychiatric, cognitive, and sleep disorders [41–43,61]. There is evidence indicating that more
than half of the patients affected by focal dystonia suffer from psychiatric disorders, whose onset
precedes that of dystonia [42].
Depression occurs with higher rates in patients with primary focal dystonia, and in manifesting
and non-manifesting DYT1 mutation carriers [41]. There is also evidence indicating an increased risk
of anxiety disorders, OCD, and social phobia in dystonia [41]. Specific deficits in executive functions
and executive dysfunction that are possibly linked to fronto-striatal dysfunctions have been reported
in idiopathic and DYT1 dystonia [45]. Alterations in working memory, processing speed, visual
motor ability, and short-term memory have also been described in adult-onset primary cranial cervical
dystonia [46]. Altogether, these results deserve specific assessment of the possible impact of executive
dysfunction in the capacity to consent in patients with dystonia.
Subthalamic nucleus [9] and pallidal [10] DBS proved useful in the treatment of generalized and
segmental primary dystonia, while inconclusive evidence exists for focal dystonia and secondary
forms [11,12]. Ventral pallidal stimulation, GPi, medullary lamina, or a combination of these have been
proposed for the treatment of primary dystonia [62]. Initial data also supports long-term tolerability
and the sustained effectiveness of subthalamic nucleus DBS in patients with medically refractory
isolated dystonia [9]. The most common side effect of DBS in patients with dystonia is dysarthria,
which is due to the unintentional diffusion of stimulation to adjacent bulbar bundles [9,63]. Among
the other side effects are infections, the accidental deactivation or breakage of the electrode/internal
pulse generator, wrong positioning, and lead migration [63].
Although some studies reported neuropsychological and psychiatric abnormalities in patients
with dystonia who have been treated with GPi DBS, including a decline in verbal semantic fluency and
increase in suicide rates, a recent neuropsychological study of a heterogeneous patient population did
not confirm these risks [64]. The lack of conclusive evidence regarding these possible complications
should be adequately considered in the patient information process and the acquisition of informed
consent, using a precautionary viewpoint. We found no empirical studies specifically aimed at
assessing the decision-making capacity of patients with dystonia undergoing DBS.
3.3. Essential Tremor
ET is among the most common neurological disorders; the main clinical feature is a postural or
kinetic tremor, affecting the hands and forearms, although other body regions may also be involved.
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It has been shown that patients affected by ET may also suffer the presence of non-motor symptoms,
including mood and anxiety disorders, and mild cognitive deficits [47]. MDD is frequent in patients
with ET, affecting about half of the patients [48]. Depressive symptoms have been reported even
more frequently, with rates of up to 79% [49]. Anxiety symptoms and social phobia have also been
reported in ET [46]. Neuropsychological studies of patients with ET showed attentional and executive
dysfunction, and an increased risk for mild cognitive impairment and dementia [50].
Unilateral or bilateral DBS targeted to the ventralis intermedius nucleus (VIM) of the thalamus
showed significant symptom improvement in patients with ET, and it is considered a useful treatment
option [7,8]. However, there is evidence indicating a possible loss of effectiveness over time of VIM
thalamic DBS [65], with rates up to 70% of the treated patients [66]. This possible course should be
adequately communicated and evaluated by the patient during the acquisition of consent to surgery.
Several surgical and non-surgical side effects have been reported following thalamic DBS for
ET, including speech and gait problems, ataxia, balance disorders, and paresthesia [67,68]. Since
unilateral VIM DBS usually presents with less adverse events, but is also associated with poorer
symptoms control [56], we deem that the choice between the two procedures should be part of a shared
decision-making with the patient. We found no empirical studies specifically aimed at assessing the
decision-making capacity of patients with ET undergoing DBS.
3.4. Tourette Syndrome
TS is a neuropsychiatric disorder that is characterized by multiple, involuntary motor tics
and at least one vocal tic, persisting for more than one year since the onset of the first tic
(before age 18 years), according to current DSM-5 criteria [69]. Patients with TS often suffer from
psychiatric comorbidities, including OCD, attention deficit hyperactivity disorder, and autism spectrum
disorders [70]. A significant disease burden and impaired quality of life have been consistently reported
in patients with TS, and their treatment may be complicated by a significant interindividual variability
of symptoms and comorbidities [71]. Psychotherapy and pharmacological therapies are first-line
treatment in patients with TS [71,72].
Data coming from the analysis of a reduced number of patients indicate that DBS is a suitable
option for treatment-resistant adults with TS who are severely affected [73,74]. Nevertheless, DBS in
TS is considered, to date, an experimental treatment [73]. A wide variability of potential DBS stimulus
sites exists in TS [73,74], and is associated with a significant variability of effects. Several adverse effects
with differences based on the DBS stimulus target have been reported; paresthesia and dysarthria [74]
are the most common, followed by, gaze disturbances, visual symptoms, increased or decreased libido,
mood alterations, and one case of psychosis and a suicide attempt [75]. There seems moreover to be a
higher risk for post-surgical infection with DBS for TS compared with other movement disorders [75].
We found no empirical studies specifically aimed at assessing the decision-making capacity of patients
with TS undergoing DBS.
3.5. Obsessive-Compulsive Disorder
Obsessive-compulsive disorder is characterized by the presence of obsessions, compulsions,
or both, with a lifetime prevalence from 2% to 3% [76]. Untreated OCD, or treatment-refractory
OCD, tend to have a chronic and disabling course [77]. First-line treatment involves integrated
cognitive-behavioral psychotherapy and pharmacological therapy; however, about 10% of the patients
treated do not respond to standard and second-line augmentation treatments [78].
In the last decade, DBS has been increasingly used in treatment-refractory patients, proving a
potentially effective technique from a clinical and cost-efficacy perspective, with response rates up to
60% [13]. DBS in the treatment of severe treatment-resistant OCD received FDA’s humanitarian device
exemption approval in 2009 [79].
In patients with OCD, the DBS has been targeted to striatal areas, including the ventral internal
capsule/ventral striatum, the nucleus accumbens, the subthalamic nucleus, the anterior limb of the
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internal capsule, and the inferior thalamic peduncle [3]. Unlike the application of DBS in other
disorders, the currently available data seems to suggest the absence of significant differences in efficacy
among application sites [80]. Adverse effects have been described as mild, transient, and reversible;
however, a meta-analysis on 31 published studies, including 116 patients, reported a significant risk of
anxiety and hypomanic symptoms post-DBS [80].
The pathophysiology of OCD has long been hypothesized to be due to alterations in the
orbitofrontal cortex functioning, and patients with OCD appear to have altered decision-making
capacity [81]. Interestingly, anterior capsulotomy has been associated with improvement in this
capacity [81]. In addition, patients with OCD tend to present higher risk-averse behavior [82]; this
condition could limit the possibility of access to a potentially useful procedure that is considered
abnormally risky, which could be the case for DBS.
No specific cognitive deficits nor cognitive impairment have been consistently associated with
OCD, but several lines of evidence indicate a reduced performance on neuropsychological tests [83].
The possible impact of obsessions and compulsions, as well as neuropsychological features of OCD on
patients’ treatment decision-making capacity deserves further assessment. We found no studies that
have assessed the capacity to give consent to treatment in patients with OCD.
3.6. Major Depressive Disorder
MDD is the leading cause of disability among psychiatric disorders, and it has been estimated that
about one-third of patients suffering from MDD do not respond to antidepressants and face a higher
disease burden [84]. Some studies showed that DBS may be a viable treatment option in patients with
treatment-resistant depression [85–87]. Nonetheless, a recent multisite, randomized, sham-controlled
trial of subcallosal cingulate DBS for treatment-resistant depression showed no statistically significant
antidepressant efficacy [88]. Since there is limited data coming mainly from non-controlled studies,
and a sham-controlled trial proved no efficacy, DBS in treatment-resistant depression is considered an
experimental treatment to be evaluated in clinical trials.
DBS in depressed patients has been targeted to the subgenual cingulate gyrus, anterior limb
of internal capsule, nucleus accumbens, ventral capsule/ventral striatum, and superolateral branch
of the medial forebrain bundle. Among the most frequent side effects were: infection, suicide, and
hypomania [89]. The lack of clear evidence of efficacy, the invasive nature of the procedure, and the
possible adverse events deserve specific attention when acquiring informed consent to clinical research
to DBS in MDD. A study showed that patients with treatment-resistant depression who had been
enrolled in studies on treatment with DBS showed a non-compromised decision-making capacity
and autonomy of decision-making [90]. Despite this encouraging result, a tendency to therapeutic
misconception in patients with treatment-resistant MDD has been reported [21,91], as they tended to
consider the purpose of the study as specifically aimed at treating the subjects involved, rather than
exploring the effectiveness of an experimental intervention.
A recent study of the impact of DBS on MDD patients’ autonomy showed that, by possibly
reducing disabling symptoms such as anhedonia and fatigue, DBS could increase autonomy rather
than threaten it [85]. The role of anhedonia and fatigue, their possible interaction, and their effect on
patients’ decision-making ability and autonomy, considering the results in MDD, is a matter of interest
in ethical empirical research that ought to be addressed also in other DBS candidate disorders in which
depressive symptoms have been reported.
4. Conclusions
Data concerning DBS in different diseases are characterized by a heterogeneity of the levels of
evidence of safety and efficacy, with more information existing for movement disorders, especially PD.
Whereas in the case of psychiatric indications, there is much less robust evidence. DBS in psychiatric
disorders applies only to therapeutic research; the research protocols should accordingly provide
an adequate evaluation of the ability of patients to provide a valid consent to clinical research. The
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hypothesis of the possible ineffectiveness of DBS, which is greater in the case of research protocols,
including the possibility of necessity of explanting the device, should be part of the informed consent
to DBS [92].
Evaluations of the capacity to consent to treatment or clinical research could be carried out with
reliable procedures and evaluation tools, considering the existence of cognitive impairments and
psychiatric symptoms that could be associated with decision-making incapacity. Considering that the
existence of therapeutic misconception in DBS for MDD has been demonstrated, its presence can also
be hypothesized in other disorders in which experimentation is carried out, and should therefore be
systematically evaluated. The possible development of post-DBS psychiatric symptoms with a likely
impact on patients’ autonomy, especially hypomania, which emerged in several studies as well as
alterations in executive functions and working memory, should be carefully monitored.
In conclusion, the hypothesis of a possible DBS influence on patients’ decisional autonomy
deserves further empirical research. Overall, there is a significant lack of data on the ability of patients
with DBS to decide whether to be treated or included in research protocols, which is an important
limitation and a starting point for future studies.
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